Bottom line
PBMIX vs SMOT: the short answer
PBMIX (Polen U.S. SMID Company Growth Fund) and SMOT (VanEck Morningstar SMID Moat ETF) are both mutual funds.
SMOT is cheaper at 0.49% vs 1.05% — a difference of $56 a year per $10,000 invested.
Over one year, SMOT returned +6.5% vs +1.5% for PBMIX (reporting dates differ).
Updated Nov 19, 2026
PBMIX vs SMOT side by side
| PBMIX | SMOT | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fundvantage | VanEck |
| Category | Small-Cap | Small-Cap |
| Expense ratio | 1.05% | 0.49% |
| Annual cost per $10k | $105 | $49 |
| 10-yr cost on $10k (prospectus) | $2,343 | $616 |
| Max front load | — | None |
| 12b-1 fee | — | — |
| 1-yr return | +1.5% | +6.5% |
| 5-yr return (annualized) | — | — |
| 10-yr return (annualized) | — | — |
| Best quarter | +14.7% | +11.5% |
| Worst quarter | −29.5% | −6.3% |
| Net assets (fund) | — | $334.4M |
| Number of holdings | — | 110 |
| Portfolio turnover | 58% | 77% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PBMIX | SMOT | Difference |
|---|---|---|---|
| 2024 | +1.5% | +10.8% | −9.3% |
| 2023 | +27.5% | +17.3% | +10.2% |
Source: Fund prospectus bar charts
Holdings overlap
PBMIX and SMOT share none of their top holdings.
PBMIX top 10
SMOT top 10
- Acuity Inc — 1.70%
- Bio-Techne Corp — 1.66%
- Masco Corp — 1.56%
- Biogen Inc — 1.45%
- Royalty Pharma PLC — 1.45%
- Block Inc — 1.42%
- Corteva Inc — 1.42%
- Amcor PLC — 1.39%
- Gentex Corp — 1.39%
- Norwegian Cruise Line Holdings Ltd — 1.38%
FAQ
What is the difference between PBMIX and SMOT?
PBMIX (Polen U.S. SMID Company Growth Fund) and SMOT (VanEck Morningstar SMID Moat ETF) are both mutual funds. SMOT is cheaper at 0.49% vs 1.05% — a difference of $56 a year per $10,000 invested.
Which is cheaper, PBMIX or SMOT?
SMOT has the lower expense ratio (0.49%).
Should I own both PBMIX and SMOT?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.